Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Capsida has reported a patient death in a gene therapy trial for epilepsy, but the exact cause of death has not been disclosed. The patient had received the gene therapy cap-002. ## The FDA is looking to streamline the development of non-opioid painkillers, while Avidity has seen functional improvements in their DMD therapy. ## The White House is reportedly considering restrictions on Chinese licensing deals in the pharmaceutical industry. ## Lilly is seeking individuals willing to challenge the status quo of medicine. ## Merck has abandoned a $1.3 billion R&D center in London, resulting in layoffs. Novo has cut 9,000 employees, and New York City's life sciences scene is growing. Thank you for tuning in to today's episode of Pharma and Biotech daily. Stay informed and have a great day!

Support the show